Real-world Experience with Afatinib after Failure of First-Generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor

被引：0

作者：

Liam, C. ^{[1
]}

Ho, G. ^{[2
]}

Chai, C. ^{[3
]}

Alip, A. Bt ^{[2
]}

Pang, Y. ^{[1
]}

机构：

[1] Univ Malaya, Fac Med, Dept Med, Kuala Lumpur, Malaysia

[2] Univ Malaya, Fac Med, Dept Oncol, Kuala Lumpur, Malaysia

[3] Univ Malaysia Sarawak, Fac Med & Hlth Sci, Dept Med, Kota Samarahan, Malaysia

来源：

关键词：

afatinib; resistance mechanism; second line treatment;

D O I：

10.1016/j.jtho.2018.08.947

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P1.15-15

引用

页码：S616 / S617

页数：2